Our company was founded by scientists who are driven to find treatments for facioscapulohumeral muscular dystrophy.

​

Our commercial efforts are driven by science.

​

There is currently no therapeutic treatment or cure for FSHD.

​

Our goal is to develop the world's first gene therapy to treat FSHD using novel patented CRISPRi technology.

​

​